FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/04/024668 [Registered on: 16/04/2020] Trial Registered Prospectively
Last Modified On: 11/04/2020
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Single Arm Study 
Public Title of Study   Role of pippalyadi anjana And Triphala Rasayana in first stage of cataract  
Scientific Title of Study   Role Of Pippalyadi Anjana And Triphala Rasayana in Timira(Immature Senile Cataract) 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
Nil  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Akanksha Singh 
Designation  Pg Scholar  
Affiliation  Uttrakhand ayurved university Harrawala Dehradun 
Address  OPD no-5,Department of Shalakya Tantra,Rishikul Campus uttrakhand ayurved university Haridwar

Hardwar
UTTARANCHAL
249401
India 
Phone  7895045785  
Fax    
Email  akanksha0729@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Gunjan Sharma 
Designation  Professor 
Affiliation  Uttrakhand ayurved university, Harrawala Dehradun 
Address  Opd No-5, Department of Shalakya Tantra,Rishikul campus Uttrakhand ayurved university Haridwar

Hardwar
UTTARANCHAL
249401
India 
Phone  8218428029  
Fax    
Email  gunjan06purity@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Gunjan Sharma 
Designation  Professor 
Affiliation  Uttrakhand ayurved university, Harrawala ,Dehradun 
Address  Opd No-5,Department of Shalakya Tantra,Rishikul campus Uttrakhand ayurved university Haridwar

Hardwar
UTTARANCHAL
249401
India 
Phone  8218428029  
Fax    
Email  gunjan06purity@gmail.com  
 
Source of Monetary or Material Support  
Nil 
 
Primary Sponsor  
Name  Rishikul campus UAU Harrawala Dehradun 
Address  Opd no 5 Department Of Shalakya Tantra Rishikul Campus Uttarakhand Ayurveda University Haridwar  
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Akanksha Singh  Rishikul Campus Uttarakhand Ayurved University  Opd No-5 Department of Shalakya Tantra Rishikul Campus Uttrakhand Ayurveda University Haridwar
Hardwar
UTTARANCHAL 
7895045785

akanksha0729@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional ethics committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  , (1) ICD-10 Condition: H259||Unspecified age-related cataract,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Not Applicable  Not Applicable 
Intervention  Pippalyadi Anjana and Triphala Rasayana Vati  First deepen- pachana(3-7 days),according to the koshth of patient,then topical application of pippalyadi anjana in the form of ointment into the conjunctival fornices from inner canthus to outer canthus in the dose of 3 vidang matra twice in a day with triphala rasayana vati 500 mg BD with normal water for 2 months.  
 
Inclusion Criteria  
Age From  45.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  1.6/9-6/60 with best corrected visual acuity.
2.patient having sign and symptoms of pratham,dwitiya and tritiya patalagata timira
3.Stage of immature cataract  
 
ExclusionCriteria 
Details  1.patient less than 45 years and more than 70 years.
2.Less than 6/60 with best corrected visual acuity.
3.patient having signs and symptoms of mature and hyper mature cataract.
4.Known case of congenital,developmental,traumatic,complicated and metabolic cataract.
5.patient associated with Hypertension and diabetes mellitus.
6.patient under chemotherapy, steroids and immunosuppressive drugs therapy
7.known case of uvietis,glaucoma and retinopathies. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Delay the progression of senile cataract  2 months 
 
Secondary Outcome  
Outcome  TimePoints 
Relief in the associated symptoms of senile cataract   2 months  
 
Target Sample Size   Total Sample Size="40"
Sample Size from India="40" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 1 
Date of First Enrollment (India)   20/04/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="2"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary   Globally, WHO has identified cataract as a first most common cause of preventable blindness among five major blinding eye conditions.Senile cataract is one of the major causes for the age related visual impairment and blindness. In India,there is 50-80% of bilateral blindness is due to cataract. Lack of established conservative treatment for senile cataract evoked the necessity to find an option through treatment modalities in the management. In ayurvedic classics, among various treatment modalities anjana is the foremost procedure which drains out doshas from vartmagat siras,srotas and shringataka marma through mouth, nostrils and eyes.As this is a senile disease swabhav balpravritta vyadhi So, in this aspect orally  Rasayana  is given  which is  rejuvenating, nutritious and possess strong antioxidant activity.Considering all these facts, the pippalyadi anjana and triphala rasayana both from yogratnakar has been selected for the present study. 
Close